Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compounds and pharmaceutical compositions for the treatment of viral infections

A technology of compounds and antiviral agents, applied in the direction of carbohydrate active ingredients, botanical equipment and methods, applications, etc., can solve the problem that vaccines cannot help patients

Inactive Publication Date: 2010-01-13
INDENIX PHARM LLC +2
View PDF152 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Plus, the vaccine won't help patients who've already had the virus

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds and pharmaceutical compositions for the treatment of viral infections
  • Compounds and pharmaceutical compositions for the treatment of viral infections
  • Compounds and pharmaceutical compositions for the treatment of viral infections

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0675] Preparation of A550(NM204), a hydroxy-tBuSATE N-benzyl phosphoramidate derivative of L-2′,3′-dideoxyadenosine L-ddA

[0676]

[0677] NM204, A550

[0678] Synthetic scheme

[0679]

[0680] Synthesis of Carboxylic Acid 2

[0681]

[0682] Methyl 2,2-dimethyl-3-hydroxypropionate (965 μL, 7.57 mmol) was added dropwise to 4,4′-dimethoxytrityl chloride (2.82 g, 8.33 mmol) at room temperature In a stirred solution in dry pyridine (7.6 mL). The reaction mixture rapidly turned into a red solution and then an orange suspension (approximately 30 minutes), and this suspension continued to stir overnight. Carefully pour the mixture over saturated NaHCO 3 Aqueous solution (30mL), with Et 2 O (3 x 20 mL) extracted the product. The combined organic extracts were washed with brine (20 mL), dried (Na 2 SO 4 ), and the volatiles were removed under reduced pressure. The resulting oil was co-evaporated with toluene and the residue was subjected to flash column chromatogr...

Embodiment 2

[0696] B102, Preparation of Hydroxy-tBuSATE N-Benzyl Phosphoramidate Derivatives of 2′-C-Methylcytidine

[0697]

[0698] Process A:

[0699] Synthesis of H-phosphonic acid monoester 5

[0700]

[0701] carboxylic acid 3 Synthesis:

[0702] To 2,2-dimethyl-3-hydroxypropionic acid methyl ester ( 1 , 15ml, 117.6mmol) to a stirred solution in a mixture of anhydrous dichloromethane (590ml) and triethylamine (23ml), triphenyldichloromethane (1.2 equivalents, 39.3g) and 4-dimethyl Aminopyridine (0.1 equiv, 1.44 g). The reaction mixture was refluxed overnight. Carefully pour the mixture over saturated NaHCO 3 On aqueous solution, the product was extracted with dichloromethane and washed with water. The combined organic extracts were evaporated under reduced pressure to give the crude compound 2 , the crude product was used in the next step without further purification. The resulting oil was dissolved in a mixture of dioxane (350ml) and aqueous NaOH (30%, 350ml). The...

Embodiment 3

[0777] B299, Preparation of Hydroxy-tBuSATE N-Benzyl Phosphoramidate Derivatives of 2′-C-Methylguanosine

[0778]

[0779] Process A

[0780] Synthesis scheme:

[0781]

[0782] 2'-C-methylguanosine (NM108) (3g, 10.10mmol) and compound 5 [about 5 For the synthesis of , see Example 2] (6.48 g, 11.10 mmol) was co-evaporated with anhydrous pyridine and dissolved in this solvent (152 mL). Pivaloyl chloride (2.48 mL, 20.18 mmol) was added dropwise at -15 °C and the solution was stirred at the same temperature for 2 h. The reaction mixture was diluted with dichloromethane and washed with aqueous ammonium chloride (NH 4 Cl 0.5M) to neutralize. In dichloromethane / 0.5M NH 4 After extraction with aqueous Cl solution, the organic phases were combined and washed with Na 2 SO 4 Dry, evaporate under reduced pressure (bath temperature not exceeding 30°C) and co-evaporate twice with toluene. The crude mixture was purified by flash column chromatography on silica gel (eluent: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and / or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

Description

[0001] Cross References to Related Applications [0002] This patent application claims priority to the following patent applications: 1) U.S. Provisional Application No. 60 / 877,944, filed December 28, 2006; 2) U.S. Provisional Application No. 60 / 936,290, filed June 18, 2007; and 3) U.S. Provisional Application No. 60 / 985,891, filed November 6, 2007. The disclosures of the above-mentioned applications are incorporated herein by reference in their entirety. field of invention [0003] Provided herein are compounds, methods and pharmaceutical compositions for treating viral infections, including hepatitis C virus infection and hepatitis B virus infection, in a host in need thereof. In specific embodiments, nucleoside phosphoramidate or phosphonamide compounds are provided that allow accumulation of the drug in the liver. Background technique [0004] Flaviviridae [0005] The Flaviviridae family of viruses contains at least three distinct genera: Pestivirus, which causes d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A01N43/04A61K31/70C07H19/04C07H19/10C07H19/20C07H19/048
Inventor 吉恩-皮埃尔·索莫多西吉尔斯·格索林克莱尔·皮埃拉克里斯蒂安·佩里高德苏珊妮·佩罗特斯
Owner INDENIX PHARM LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com